A phase II evaluation of pemetrexed (LY231514, IND #40061) in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: A study of the gynecologic oncology group

被引：4
|
作者：
Miller, D. S.
Blessing, J. A.
Krasner, C. N.
Mannel, R. J.
机构：
[1] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA
[2] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
[3] Massachusetts Gen Hosp, Boston, MA 02114 USA
[4] Univ Oklahoma, Oklahoma City, OK USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.5524
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5524
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase II evaluation of dalantercept in the treatment of persistent or recurrent epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study
    Burger, Robert A.
    Deng, Wei
    Makker, Vicky
    Collins, Yvonne
    Gray, Heidi
    Debernardo, Robert
    Martin, Lainie P.
    Aghajanian, Carol
    GYNECOLOGIC ONCOLOGY, 2018, 150 (03) : 466 - 470
  • [32] A phase II evaluation of weekly docetaxel in the treatment of recurrent or persistent endometrial carcinoma: A study by the Gynecologic Oncology Group
    Garcia, Agustin A.
    Blessing, John A.
    Nolte, Susan
    Mannel, Robert S.
    GYNECOLOGIC ONCOLOGY, 2008, 111 (01) : 22 - 26
  • [33] Quality of life, symptoms and care needs in patients with persistent or recurrent platinum-resistant ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study
    von Gruenigen, Vivian E.
    Huang, Helen Q.
    Cella, David
    Zevon, Michael A.
    LaChance, Jason A.
    Walker, Joan L.
    Salani, Ritu
    Modesitt, Susan C.
    Morris, Robert T.
    Bradley, William H.
    Boente, Matthew P.
    Wenzel, Lari
    GYNECOLOGIC ONCOLOGY, 2018, 150 (01) : 119 - 126
  • [34] Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma
    Sorensen, P
    Hoyer, M
    Jakobsen, A
    Malmström, H
    Havsteen, H
    Bertelsen, K
    GYNECOLOGIC ONCOLOGY, 2001, 81 (01) : 58 - 62
  • [35] A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: A gynecologic oncology group study
    Tait, David L.
    Blessing, John A.
    Hoffman, James S.
    Moore, Kathleen N.
    Spirtos, Nick M.
    Lachance, Jason A.
    Rotmensch, Jacob
    Miller, David S.
    GYNECOLOGIC ONCOLOGY, 2011, 121 (01) : 118 - 121
  • [36] Dactinomycin in the treatment of recurrent or persistent endometrial carcinoma: A Phase II study of the Gynecologic Oncology Group
    Moore, DH
    Blessing, JA
    Dunton, C
    Buller, RE
    Reid, GC
    GYNECOLOGIC ONCOLOGY, 1999, 75 (03) : 473 - 475
  • [37] Phase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: A gynecologic group study
    Fracasso, PM
    Blessing, JA
    Morgan, MA
    Sood, AK
    Hoffman, JS
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (15) : 2856 - 2859
  • [38] A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study
    Rose, PG
    Blessing, JA
    Ball, HG
    Hoffman, J
    Warshal, D
    DeGeest, K
    Moore, DH
    GYNECOLOGIC ONCOLOGY, 2003, 88 (02) : 130 - 135
  • [39] Activity of docetaxel plus trabectedin in recurrent or persistent ovarian and primary peritoneal cancer: A phase II study of the Gynecologic Oncology Group (GOG)
    Monk, B. J.
    Sill, M.
    Walker, J. L.
    Hanjani, P.
    Edwards, R. P.
    Rotmensch, J.
    De Geest, K.
    Bonebrake, A. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [40] Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: A gynecologic oncology group phase II trial
    Markman, M
    Blessing, JA
    Moore, D
    Ball, H
    Lentz, SS
    GYNECOLOGIC ONCOLOGY, 1998, 69 (03) : 226 - 229
12345